|
1
|
Ministry of Health Malaysia, National
Cancer Registry. Malaysian cancer statistics - data and figure
peninsular Malaysia. 2006, http://www.makna.org.my/PDF/MalaysiaCancerStatistics.pdfuri.
Accessed, May 01, 2013
|
|
2
|
Cai GX and Cai SJ: Multi-modality
treatment of colorectal liver metastases. World J Gastroenterol.
18:16–24. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Amersi F, Stamos MJ and Ko CY: Palliative
care for colorectal cancer. Surg Oncol Clin N Am. 13:467–477. 2004.
View Article : Google Scholar
|
|
4
|
Ronnekleiv-Kelly SM and Kennedy GD:
Management of stage IV rectal cancer: palliative options. World J
Gastroenterol. 17:835–847. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cunningham D, Atkin W, Lenz HJ, et al:
Colorectal cancer. Lancet. 375:1030–1047. 2010. View Article : Google Scholar
|
|
6
|
Kannagi R: Carbohydrate antigen sialyl
Lewis a - its pathophysiological significance and induction
mechanism in cancer progression. Chang Gung Med J. 30:189–209.
2007.PubMed/NCBI
|
|
7
|
Sato H, Usuda N, Kuroda M, et al:
Significance of serum concentrations of E-selectin and CA19–9 in
the prognosis of colorectal cancer. Jpn J Clin Oncol. 40:1073–1080.
2010.PubMed/NCBI
|
|
8
|
Wasserberg N and Kaufman HS: Palliation of
colorectal cancer. Surg Oncol. 16:299–310. 2007. View Article : Google Scholar
|
|
9
|
Rosenberg SA, Restifo NP, Yamg JC, et al:
Adoptive cell transfer: a clinical path to effective cancer
immunotherapy. Nat Rev Cancer. 8:299–308. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hunder NN, Wallen H, Cao J, et al:
Treatment of metastatic melanoma with autologous CD4+T
cells against NY-ESO-1. N Engl J Med. 358:2698–2703. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Srivastava S, Lundqvist A and Childs RW:
Natural killer cell immunotherapy for cancer: a new hope.
Cytotherapy. 10:775–783. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alves PC, Andrade LA, Petta CA, et al: Ex
vivo expansion of CD56+NK and NKT-like lymphocytes from
peripheral blood mononuclear cells of patients with ovarian
neoplasia. Scand J Immunol. 74:244–252. 2011.PubMed/NCBI
|
|
13
|
Somanchi SS, Senyukov VV, Denman CJ and
Lee DA: Expansion, purification, and functional assessment of human
peripheral blood NK cells. J Vis Exp. 25402011.PubMed/NCBI
|
|
14
|
Terunuma H, Deng X, Dewan Z, et al:
Potential role of NK cells in the induction of immune responses:
implications for NK cell-based immunotherapy for cancers and viral
infections. Int Rev Immunol. 27:93–110. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Teschner D, Wenzel G, Distler E, et al: In
vitro stimulation and expansion of human tumour-reactive
CD8+cytotoxic T lymphocytes by anti-CD3/CD28/CD137
magnetic beads. Scand J Immunol. 74:155–164. 2011.PubMed/NCBI
|
|
16
|
Hippen KL, Merkel SC, Schirm DK, et al:
Massive ex vivo expansion of human natural regulatory T cells
(Tregs) with minimal loss of in vivo functional
activity. Sci Transl Med. 3:83ra412011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takada M, Terunuma H, Deng X, et al:
Refractory lung metastasis from breast cancer treated with
multidisciplinary therapy including an immunological approach.
Breast Cancer. 18:64–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dewan MZ, Terunuma H, Toi M, Tanaka Y, et
al: Potential role of natural killer cells in controlling growth
and infiltration of AIDS-associated primary effusion lymphoma
cells. Cancer Sci. 97:1381–1387. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun Z, Shi L, Zhang H, et al: Immuno
modulation and safety profile of adoptive immunotherapy using
expanded autologous activated lymphocytes against advanced cancer.
Clin Immunol. 138:23–32. 2011. View Article : Google Scholar
|
|
20
|
Rao B, Han M, Wang L, et al: Clinical
outcomes of active specific immunotherapy in advanced colorectal
cancer and suspected minimal residual colorectal cancer: a
meta-analysis and system review. J Transl Med. 9:172011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jursik C, Prchal M, Grillari-Voglauer R,
et al: Large-scale production and characterization of novel
CD4+cytotoxic T cells with broad tumor specificity for
immunotherapy. Mol Cancer Res. 7:339–353. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iovino F, Meraviglia S, Spina M, et al:
Immunotherapy targeting colon cancer stem cells. Immunotherapy.
3:97–106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sangiolo D: Cytokine induced killer cells
as promising immunotherapy for solid tumors. J Cancer. 2:363–368.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Barkholt L, Alici E, Conrad R, et al:
Safety analysis of ex vivo-expanded NK and NK-like T cells
administered to cancer patients: a phase I clinical study.
Immunotherapy. 1:753–764. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cruz CR, Hanley PJ, Liu H, et al: Adverse
events following infusion of T cells for adoptive immunotherapy: a
10-year experience. Cytotherapy. 12:743–749. 2010.PubMed/NCBI
|
|
26
|
Rabinowich H, Sedlmayr P, Herberman RB and
Whiteside TL: Increased proliferation, lytic activity, and purity
of human natural killer cells cocultured with mitogen-activated
feeder cells. Cell Immunol. 135:454–470. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cho D, Kim SK and Carson WE III: NK
cell-based immunotherapy for treating cancer: will it be promising?
Korean J Hematol. 46:3–5. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Terme M, Ullrich E, Delahaye NF, et al:
Natural killer cell-directed therapies: moving from unexpected
results to successful strategies. Nat Immunol. 9:486–494. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou J and Zhong Y: Breast cancer
immunotherapy. Cell Mol Immunol. 1:247–255. 2004.
|
|
30
|
McNeel DG: Cellular immunotherapies for
prostate cancer. Biomed Pharmacother. 61:315–322. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chu CS, Kim SH, June CH and Coukos G:
Immunotherapy opportunities in ovarian cancer. Expert Rev
Anticancer Ther. 8:243–257. 2008. View Article : Google Scholar
|
|
32
|
Katipamula R and Markovic SN: Emerging
therapies for melanoma. Expert Rev Anticancer Ther. 8:553–560.
2008. View Article : Google Scholar
|
|
33
|
Cooper LJ: Adoptive cellular immunotherapy
for childhood malignancies. Bone Marrow Transplant. 41:183–192.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stift A, Sachet M, Yagubian R, et al:
Dendritic cell vaccination in medullary thyroid carcinoma. Clin
Cancer Res. 10:2944–2953. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wysocki PJ, Zolnierek J, Szczylik C, et
al: Recent developments in renal cell cancer immunotherapy. Expert
Opin Biol Ther. 7:727–737. 2007. View Article : Google Scholar : PubMed/NCBI
|
